Micals Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 17-07-2024
- Paid Up Capital ₹ 2.00 M
as on 17-07-2024
- Company Age 26 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.50 M
as on 17-07-2024
- Revenue 97.34%
(FY 2022)
- Profit -3304.14%
(FY 2022)
- Ebitda -517.68%
(FY 2022)
- Net Worth -2191.35%
(FY 2022)
- Total Assets 85.77%
(FY 2022)
About Micals Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹5.50 M.
Upendra Bhayani and Veena Bhayani serve as directors at the Company.
- CIN/LLPIN
U24239MH1998PTC114070
- Company No.
114070
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Mar 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Micals Pharma Private Limited offer?
Micals Pharma Private Limited offers a wide range of products and services, including Office Automation Products & Devices, Scanner, Thermometers & Flowmeters, Infrared Thermometer & Thermal Camera Raw Materials, Presentation Boards & Accessories, Interactive Board, Mobile Tablet, Digital Tablet, Xerox Machines, Digital Photocopier Machine.
Who are the key members and board of directors at Micals Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Upendra Bhayani  | Director | 20-Mar-1998 | Current |
| Veena Bhayani | Director | 20-Mar-1998 | Current |
Financial Performance of Micals Pharma.
Micals Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 97.34% increase. The company also saw a substantial fall in profitability, with a 3304.14% decrease in profit. The company's net worth observed a substantial decline by a decrease of 2191.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Micals Pharma?
In 2022, Micals Pharma had a promoter holding of 95.95% and a public holding of 4.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 07 Jun 2021 | ₹0.50 M | Open |
Bank Of India Creation Date: 23 Aug 1999 | ₹5.00 M | Open |
How Many Employees Work at Micals Pharma?
Unlock and access historical data on people associated with Micals Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Micals Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Micals Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
